Item 7.01. Regulation FD Disclosure.

On January 22, 2021, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for oral, once-daily ORLADEYO™ (berotralstat) 150 mg for prophylactic treatment of hereditary angioedema in adults and pediatric patients 12 years and older. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits

Exhibit No.    Description

                 Press release dated January 22, 2021 entitled "BioCryst Announces
  99.1         Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic
               Treatment of Hereditary Angioedema"
104            Cover Page Interactive Data File (embedded within the Inline XBRL
               document)

© Edgar Online, source Glimpses